Regenxbio rises on $100 million AbbVie milestone for eye disease drug
29/06/2026 15:09
BUZZ- Regenxbio rises on $100 million AbbVie milestone for eye disease drug ** Shares of Regenxbio RGNX.O jump 5.9% to $11.10
** The drug developer will receive $100 million milestone payment from partner AbbVie ABBV.N after dosing first patient in a mid-to-late-stage study of surabgene lomparvovec, its experimental one-time gene therapy for diabetic retinopathy
** The diabetes-related eye disease is a leading cause of vision loss among working-age adults
** The study is expected to enroll about 135 patients in the U.S.; the main goal is improvement in disease severity after one year - RGNX
** Plans to present longer-term data from its diabetic retinopathy and wet AMD programs at a retina specialists meeting in July
** Including session's move, RGNX down 22.6% YTD
(Reporting by Kunal Das in Bengaluru)
Recent news on REGENXBIO
See all newsBrief: Regenxbio says Sarepta To Pay $39 Million To Regenxbio Within 10 Days Of Effective Date
Regenxbio climbs as new director buys nearly $1 million of stock
Brief: Regenxbio Strengthens Board Of Directors With Appointment Of Greg Ciongoli
U.S. STOCKS ON THE MOVE-Strategy, Ecovyst, Azenta
U.S. STOCKS ON THE MOVE-Azenta, Qiagen NV, Capricor Therapeutics